News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioVectra Inc. Announces Oncolix Inc. Signs Manufacturing and Investment Agreement


9/23/2009 11:35:33 AM

CHARLOTTETOWN, PEI--(BUSINESS WIRE)--BioVectra, Inc., a cGMP manufacturing and development partner in Charlottetown, PEI, Canada, announces that it has reached an agreement with Oncolix Inc., a biopharmaceutical company based in Houston, Texas, to manufacture ProlantaTM for human clinical testing. As part of this agreement, BioVectra will be investing $1.5 million in Oncolix. Prolanta is a targeted therapeutic protein under development for the treatment of breast and ovarian cancer.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES